LAVA Therapeutics N.V. (NASDAQ:LVTX) saw its stock rise 4.2% following news of a share purchase agreement with XOMA Royalty ...

Detailed price information for Xoma Royalty Corporation (XOMA-Q) from The Globe and Mail including charting and trades.

Fintel reports that on August 5, 2025, Jefferies downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX) from Buy ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Xoma Royalty has agreed to acquire Lava Therapeutics.

Additionally, LAVA Therapeutics is on track to initiate Phase 1 trials of LAVA-1266 for acute myeloid leukemia by the end of the year, which could target a range of hematological malignancies.

LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the ...

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for ...

Ph.D., chief scientific officer at LAVA, will present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.

LAVA Therapeutics N.V. LVTX shares are trading higher Monday after the company and Seagen Inc SGEN announced an exclusive license agreement in which Seagen will work to develop, manufacture and ...